Patients with Community-Acquired, Health Care-Associated, Hospital-Acquired or ventilator associated pneumonia
Conditions
Interventions
Intervention type:
Name of intervention:
Dose form / Japanese Medical Device Nomenclature:
Route of administration / Site of application:
Dose per administration:
Dosing frequency / Frequency of use:
Sponsors
National Hospital Organization Mie National Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with Community-Acquired, Health Care-Associated, Hospital-Acquired or ventilator associated pneumonia
Exclusion criteria
Exclusion criteria: Patients with pulmonary tuberculosis and an infiltrate other than pneumonia, i.e., acute congestive heart failure, pulmonary infarction or interstitial pneumonia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the efficacy of the algorithm for guiding the initial empiric therapy for all cause pneumonia. | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the baseline characteristics, presence of MDR risk factors, etiology, antibiotic regimens and outcomes for: 1) each pneumonia group (CAP, HCAP, HAP and VAP patients); 2) patients with 0-1 MDR risks vs. patients with >=2 MDR risks in all cause pneumonia; and 3) non-severe pneumonia vs. severe pneumonia in all cause pneumonia. | — |
Countries
Japan
Contacts
Public ContactTakaya Maruyama
National Hospital Organization Mie National Hospital
Outcome results
None listed